All sponsors

Hansoh BioMedical R&D Company $3692.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS16
PHASE 3 / 2-37
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO0%

Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Hansoh BioMedical R&D Company on the live radar map → 📅 $3692.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
HS-20093
NCT06007729
P2RecruitingHead and Neck Squamous Cell Carcinoma1702025-12-12
HS-20093
NCT05830123
P2RecruitingOsteosarcoma; Sarcoma1702025-12-31
HS-20089
NCT06014190
P2RecruitingOvarian Cancer; Fallopian Tube Cancer4602025-12-31
HS-20105
NCT06144723
P1/2Not yet recruitingAdvanced Solid Tumor4022026-03
HS-20117
NCT06417008
P2/3RecruitingNon-Squamous Non-Small Cell Lung Cancer10802026-06-01
HS-10374 6mg tablets
NCT06926582
P2Not yet recruitingPsoriasis3052026-07-09
HS-20093
NCT06112704
P2RecruitingAdvanced Solid Tumor2202026-07-31
HS-20137
NCT07879885
P2RecruitingModerate-to-severe Plaque Psoriasis3902027-03-01
HS-20089
NCT06855069
P3RecruitingOvarian Cancer4682027-03-07
HS-20137
NCT06844799
P3Not yet recruitingModerate-to-severe Plaque Psoriasis7202027-03-31
HS-20093
NCT06526624
P3Not yet recruitingLimited-stage Small-cell Lung Cancer4062027-11-30
HS-20093 for Injection
NCT07824882
P2RecruitingNon-Small Cell Lung Cancer762028-03-30
HS-20093
NCT07464327
P3Not yet recruitingNon-Small Cell Lung Cancer4502028-12-31
HS-20089 PSOC
NCT07821606
P3Not yet recruitingPlatinum-sensitive Recurrent Ovarian Cancer4602029-12-30
Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin
NCT07283367
P1/2RecruitingCRC5022029-12-31
HS-20093 for Injection
NCT07621601
P3Not yet recruitingEsophageal Squamous Cell Carcinoma (ESCC)4942030-12-31